



FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

February 23, 2012

CardioComm Solutions Launches the HeartCheck™ Website: Begins HeartCheck™ Pen online order reservations

Launch coincides with co-sponsorship of USA Today's CardioVascular Health Supplement for National Heart Health Month.

TORONTO, ONTARIO – CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE:EKG) today announced the launch of its new HeartCheck™ website (www.theheartcheck.com). This initiative kicks off the company's 2012 Marketing Communications Campaign in support of their entry into the consumer, over-the-counter (OTC) and prescribed Health Care Market and follows the recent Food and Drug Administration (FDA) OTC clearance of the HeartCheck™ Pen Hand Held ECG device.

"The launch of the HeartCheck™ website and co-sponsorship of the CardioVascular Health insert for USA Today (February 23, 2012), are in keeping with our commitment to enhance patient and consumer awareness into cardiac arrhythmias and the risks associated with them. It also highlights how ECG and heart rhythm monitoring can be of benefit in primary and secondary disease prevention efforts" said Etienne Grima, CEO of CardioComm Solutions.

The CardioVascular Health publication stresses the importance of open patient-doctor dialogue and also addresses issues around Atrial Fibrillation ("AF"). Within the publication, there is an information segment "By The Numbers" authored by Dr. Anatoly Langer, Chairman of the CardioComm Solutions Board of Directors, which provides statistics for AF occurrence, the most common cardiac arrhythmia. The article also describes the associated risk for stroke development and how to best screen for AF.

"It has been a busy six weeks since the FDA clearance and we remain on schedule in the introduction of the HeartCheck™ products and services. The CardioVascular Health publication and the launching of our new HeartCheck™ website are great opportunities to formally introduce the HeartCheck™ PEN to the consumer audience" Grima added.

The HeartCheck™ website provides an overview of the HeartCheck™ devices, reviews intended uses of each product and introduces the GEMS™ Home application. This application enables Heart Rhythm (PEN) and ECG recordings (ECG Monitor) to be sent to the CardioComm Solutions' HeartCheck™ monitoring center - an extension to the company's medical service called C4. This service will be launched under the "HeartCheck™ Smart Monitoring" brand.

For a limited time, the website will provide an opportunity for individuals to pre-register for a HeartCheck™ Pen in anticipation of device sales later in the year. "There is a questionnaire which asks the interested buyer for their email address, their city, as well as optional information regarding their general health. With over 15 years of experience in providing medical solutions for ECG screening and ECG management for hospitals, physicians and medical call centers, we want to make this more than a device launch. We want to understand and best match the consumer's needs and leverage the HeartCheck™ Pen's very real potential to make a positive impact on quality of life, disease screening, and disease management of its owners" said Grima.

"CardioComm Solutions intends to be a leading provider of ECG Management Solutions. The new website, the soon to be launched HeartCheck™ Smart Monitoring service and the information collected from the pre-registration process will go a long way in tailoring access to the devices and to bring more value to the telemedicine and in-home monitoring market" noted Mr. Simi Grosman, member of CardioComm Solutions' Board of Directors.

About CardioComm Solutions



CardioComm Solution's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer

1-877-977-9425 x227

egrima@cardiocommsolutions.com

www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release